PMC:7228307 / 9869-10333 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T86","span":{"begin":92,"end":96},"obj":"Body_part"},{"id":"T87","span":{"begin":453,"end":457},"obj":"Body_part"}],"attributes":[{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A87","pred":"fma_id","subj":"T87","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses. In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1). These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T171","span":{"begin":6,"end":8},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T172","span":{"begin":9,"end":11},"obj":"http://purl.obolibrary.org/obo/CLO_0008882"},{"id":"T173","span":{"begin":92,"end":96},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T174","span":{"begin":198,"end":200},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T175","span":{"begin":201,"end":203},"obj":"http://purl.obolibrary.org/obo/CLO_0008882"},{"id":"T176","span":{"begin":215,"end":216},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T177","span":{"begin":429,"end":431},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T178","span":{"begin":432,"end":434},"obj":"http://purl.obolibrary.org/obo/CLO_0008882"},{"id":"T179","span":{"begin":453,"end":463},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses. In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1). These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T47","span":{"begin":169,"end":178},"obj":"Chemical"},{"id":"T48","span":{"begin":229,"end":237},"obj":"Chemical"}],"attributes":[{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses. In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1). These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T62","span":{"begin":92,"end":96},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T63","span":{"begin":341,"end":349},"obj":"http://purl.obolibrary.org/obo/GO_0085030"},{"id":"T64","span":{"begin":453,"end":457},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses. In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1). These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T54","span":{"begin":0,"end":107},"obj":"Sentence"},{"id":"T55","span":{"begin":108,"end":316},"obj":"Sentence"},{"id":"T56","span":{"begin":317,"end":464},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses. In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1). These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T85","span":{"begin":92,"end":96},"obj":"Body_part"},{"id":"T86","span":{"begin":453,"end":457},"obj":"Body_part"}],"attributes":[{"id":"A85","pred":"fma_id","subj":"T85","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses. In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1). These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types."}

{"project":"LitCovid-sentences","denotations":[{"id":"T54","span":{"begin":0,"end":107},"obj":"Sentence"},{"id":"T55","span":{"begin":108,"end":316},"obj":"Sentence"},{"id":"T56","span":{"begin":317,"end":464},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses. In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1). These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types."}